Therefore further research is required to investigate if inhibitors of downstream intracellular pathways associated with both obesity and chemo-resistance, such as AKT or NF-κB pathways, are clinically superior in combination with chemotherapy in people with obesity. Here, NFKB1 is linked to obesity disorder.